Ovarian Cancer Therapeutics To 2020
(PRWEB) May 22, 2014
“Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free Survival and Targeted Therapies”. The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carbonation and facilitate, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/ovarian-cancer-therapeutics-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-survival-and-targeted-therapies
There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients. The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS.
In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS – olaparib, Vynfinit and Treblinka, will be approved in this territory. However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA. In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period. As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer.
Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/196710
Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9 billion in 2020. Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology.
The report analyses treatment usage patterns, drug types available and pipeline and market forecasts across indications for pancreatic cancer.
The report covers and includes:
A brief introduction to ovarian cancer, including the disease’s pathogenesis, risk factors and diagnosis.
In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the disease treatment algorithm. This includes a heat map comparing the drug combination in terms of safety and efficacy.
Comprehensive review of the pipeline for ovarian cancer therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
Read More Reports with Toc: http://www.marketresearchreports.biz/analysis/196710
Reasons to Buy
The report will assist business development and enable marketing executives to strategic their product launches, by allowing them to:
Understanding the efficacy and safety of the current mono therapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm.
Understand the key signalling pathways and molecular targets currently under investigation in drug development for ovarian cancer
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Disease Path physiologies
2.1.1 Ovarian Cancer – A Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly Heterogeneity, with Multiple Mutations and Affected Signalling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.2 Inherited Genetic Mutations
2.3.3 Greater Number of Lifetime Ovulations
2.3.5 Previous Medical Conditions
2.4 Treatment Algorithm
3 Marketed Products
3.5 Paginated Liposomal Doxorubicin
3.6 Yon delis
Membrane Bioreactor (MBR) Systems Market by Configuration (Side stream And Submerged) For Product (Hollow Fiber, Flat Sheet and Multi-Tubular Systems) In Applications (Municipal Waste water and Industrial Waste water) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2019
Membrane Bioreactor (MBR) is a relatively new yet fast maturing technology in the area of waste water treatment. Prevalent technologies in waste water treatment such as conventional activated sludge (CAS) systems are gradually replaced by MBR. Conventional systems had problems in settling the activated sludge used in the secondary clarifiers. This issue has been effectively resolved by MBR technology. Commercial MBR processes employed today utilize membranes for filtration purposes which reject any solid effluent materials formed as a by-product of biological processes.
This research is designed to estimate, analyze, and forecast the market revenue of MBR systems across the global market. The research provides in-depth analysis of MBR system manufacturers, product sales, trend analysis by segments, and market revenue by geography. The report covers key applications, configuration and product segments of the MBR systems market. It also provides detailed analysis, historical data and statistically refined forecast for the segments covered. MBR systems aid in waste water treatment and assist in saving substantial amount of water through recycling and reuse.
Download Full Report with TOC @ http://www.marketresearchreports.biz/sample/sample/144869
The market size for MBR systems has been estimated on the basis of indicators in end use industries. This report also discusses various applications and product types of MBR systems. All the market revenues have been calculated by considering the whole system installation cost including numerous components and parts plus installation lobar, engineering and project management cost. The major applications considered under the MBR systems market cover the municipal waste water treatment and industrial waste water treatment. Whereas, key product segments analysed in this report include on hollow fiber, flat sheet and multi tubular.
Global and China Biodegradable Plastics Industry Report, 2013 - 2016
Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/an in 2012-2013. Among dozens of biodegradable plastic varieties developed so far, only plastarch material (PSM), polylactic acid (PLA), poly (butylenes succinate) (PBS) have realized mass industrial production. In 2013, PSM, PLA and PBS accounted for 87% of the world’s total capacity.
China as one of the world’s important suppliers of biodegradable plastics accounts for about 20% of global production capacity. In 2009-2013, its biodegradable plastic capacity grew at a compound annual growth rate of over 21%. And, under the stimulus of favorable national policies as well as expanding range of applications, many domestic enterprises have embarked on new construction or expansion of biodegradable plastics.
Download Full Report with TOC @ http://www.marketresearchreports.biz/sample/sample/192499
As a leader in domestic plastics industry, Kanga Sic & Tech Co., Ltd. mainly produces modified plastics, specialty engineering plastics, completely biodegradable plastics, carbon fiber and composite materials, of which, the 30 kit/a PBS and polybutylene succinate adipate (PBSA) has been put into operation in Zhuhai in 2011, the Phase II 90 kit/a PBSA expansion project will be launched. Meanwhile, Kanga is also increasing intensity of downstream demand expansion. The company has signed biodegradable plastic mulch demonstrative application agreements with Xinjiang Production and Construction Corps, Guizhou, Shandong and other provinces and cities in early 2014.
North America Drug Delivery Devices Market Outlook to 2018 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Others
Visit Complete Report Here @ http://www.marketresearchreports.biz/analysis-details/north-america-drug-delivery-devices-market-outlook-to-2018-metered-dose-inhaler-devices-infusion-systems-central-venous-catheters-and-others
GlobalDatas new report, North America Drug Delivery Devices Market Outlook to 2018 Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Others provides key market data on the North America Drug Delivery Devices market United States and Canada. The report provides value (USD million) data for all the market categories Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.
Countries covered include United States and Canada.
Market size and company share data for Drug Delivery Devices market categories Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections.
Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018.
2011 company shares and distribution shares data for each of the market categories and countries.
Global corporate-level profiles of key companies operating within the North America Drug Delivery Devices market.
Download Full Report with TOC @ http://www.marketresearchreports.biz/sample/sample/163853
Reasons to buy
Develop business strategies by identifying the key market categories and segments poised for strong growth.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the North America Drug Delivery Devices competitive landscape.
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: +1-866-997-4948